Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Three-minute bladder-cancer test launched in US:

This article was originally published in Clinica

Executive Summary

CR Bard's three-minute bladder-cancer test, the Bard BTA, was launched in the US at the 1st International Bladder Symposium at the end of last week. The test, developed by Seattle-based Bard Diagnostic Sciences, received US FDA approval late last year and has been on sale in Europe for one year (see Clinica No 683, p 20).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT087763

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel